vTv Therapeutics Inc. Announces Launch of Initial Public Offering

Posted by on Jul 27, 2015 in Newsroom | 0 comments

HIGH POINT, N.C. – vTv Therapeutics Inc. (the “Company”) today announced the launch of its initial public offering in the United States of 7,812,500 shares of its Class A common stock. The initial public offering price is currently expected to be between $15.00 and $17.00 per share of Class A common stock. The Company has submitted an application for listing on the NASDAQ Global Market and trading under the ticker symbol “VTVT.” The underwriters have the option to purchase from the Company up to an additional 1,171,875 shares of Class A common stock at the public offering...

Read More

Johnson & Johnson Vision Care Expansion in Jacksonville

Posted by on Jul 22, 2015 in Newsroom | 0 comments

JACKSONVILLE, FL. – Johnson & Johnson Vision Care, Inc. will expand its Jacksonville facility, creating 100 new jobs. The company will also add a capital investment of $301 million. Johnson & Johnson Vision Care is a member of the Johnson & Johnson family of companies and currently employs about 2,000 individuals in Jacksonville. Governor Scott said, “I am excited to announce that Johnson & Johnson Vision Care has chosen to create 100 new jobs and expand in Florida. Since December 2010, more than 879,000 private-sector jobs have been added in Florida and we have cut...

Read More

NC Biotech Center awards $1.8M in loans, grants across state

Posted by on Jul 21, 2015 in Newsroom | 0 comments

RESEARCH TRIANGLE PARK, N.C. – he North Carolina Biotechnology Center awarded 27 loans and grants totaling about $1.8 million to companies and universities across the state during the final quarter of its 2014-2015 fiscal year ending June 30. Altogether, the Center made 82 loans and grants totaling $6,786,852 during the year just ended. The awards support life science entrepreneurship, technology commercialization and research statewide, and lay the groundwork for major add-on funding from other sources. Company Loans The latest round of company loans includes: A $250,000 Strategic...

Read More

Scripps scientists awarded $2.8M for HIV research

Posted by on Jul 20, 2015 in Newsroom | 0 comments

JUPITER, FL. – A team of scientists from the Scripps Research Institute in Jupiter received $2.8 million in grants to develop an HIV treatment. Scripps associate professor Susana Valente is the principal investor on the study, which won funding from the National Institutes of Health. She hopes to develop a therapeutic agent that reduces latent levels of HIV that hide from the immune system. “Our approach is aimed at a novel antiviral target, a protein known as a potent activator of HIV gene expression,” Valente said. “With this new funding, we can continue to develop our approach...

Read More

Aerie pharma to expand R&D operations

Posted by on Jul 20, 2015 in Newsroom | 0 comments

RESEARCH TRIANGLE PARK, N.C. – Aerie Pharmaceuticals (Nasdaq: AERI), the Duke University spin-out working on experimental treatments for glaucoma, is expanding its research and development operations near Research Triangle Park. Aerie has signed a lease for 20,000 square feet of office and lab space in the Exchange Place building at Imperial Center business park in Durham, according to the building’s ownership group, Longfellow Real Estate Partners. It is not clear at this point whether this expansion could mean new jobs. Aerie is based in Bedminster, New Jersey, but the...

Read More

Biogen and AGTC Enter Collaboration to Develop Gene Therapies in Ophthalmology

Posted by on Jul 6, 2015 in Newsroom | 0 comments

CAMBRIDGE, MA. & GAINESVILLE, FL. – Biogen and AGTC today announced a broad collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases. The collaboration will focus on the development of a portfolio of AGTC’s therapeutic programs, including both a clinical stage candidate and a pre-clinical candidate for orphan diseases of the retina that can lead to blindness in children and adults. The agreement also includes options for early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition, as well as an equity...

Read More